These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30669676)

  • 1. HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer.
    Lin CL; Tsai ML; Lin CY; Hsu KW; Hsieh WS; Chi WM; Huang LC; Lee CH
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells.
    Chen SH; Chow JM; Hsieh YY; Lin CY; Hsu KW; Hsieh WS; Chi WM; Shabangu BM; Lee CH
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31071955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing.
    Liu B; Chen S; Rose A; Chen D; Cao F; Zwinderman M; Kiemel D; Aïssi M; Dekker FJ; Haisma HJ
    Nucleic Acids Res; 2020 Jan; 48(2):517-532. PubMed ID: 31799598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
    Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
    Pinkerneil M; Hoffmann MJ; Deenen R; Köhrer K; Arent T; Schulz WA; Niegisch G
    Mol Cancer Ther; 2016 Feb; 15(2):299-312. PubMed ID: 26772204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
    Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation.
    Hess L; Moos V; Lauber AA; Reiter W; Schuster M; Hartl N; Lackner D; Boenke T; Koren A; Guzzardo PM; Gundacker B; Riegler A; Vician P; Miccolo C; Leiter S; Chandrasekharan MB; Vcelkova T; Tanzer A; Jun JQ; Bradner J; Brosch G; Hartl M; Bock C; Bürckstümmer T; Kubicek S; Chiocca S; Bhaskara S; Seiser C
    PLoS Genet; 2022 Aug; 18(8):e1010376. PubMed ID: 35994477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
    Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
    Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
    Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumour activity of Panobinostat in oesophageal adenocarcinoma and squamous cell carcinoma cell lines.
    Lopes N; Salta S; Flores BT; Miranda-Gonçalves V; Correia MP; Gigliano D; Guimarães R; Henrique R; Jerónimo C
    Clin Epigenetics; 2024 Aug; 16(1):102. PubMed ID: 39097736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC Inhibitor-Induced Mitotic Arrest Is Mediated by Eg5/KIF11 Acetylation.
    Nalawansha DA; Gomes ID; Wambua MK; Pflum MKH
    Cell Chem Biol; 2017 Apr; 24(4):481-492.e5. PubMed ID: 28392145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining.
    Miller KM; Tjeertes JV; Coates J; Legube G; Polo SE; Britton S; Jackson SP
    Nat Struct Mol Biol; 2010 Sep; 17(9):1144-51. PubMed ID: 20802485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trans-regulation of histone deacetylase activities through acetylation.
    Luo Y; Jian W; Stavreva D; Fu X; Hager G; Bungert J; Huang S; Qiu Y
    J Biol Chem; 2009 Dec; 284(50):34901-10. PubMed ID: 19822520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single allele of Hdac2 but not Hdac1 is sufficient for normal mouse brain development in the absence of its paralog.
    Hagelkruys A; Lagger S; Krahmer J; Leopoldi A; Artaker M; Pusch O; Zezula J; Weissmann S; Xie Y; Schöfer C; Schlederer M; Brosch G; Matthias P; Selfridge J; Lassmann H; Knoblich JA; Seiser C
    Development; 2014 Feb; 141(3):604-616. PubMed ID: 24449838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer.
    Huang LC; Tam KW; Liu WN; Lin CY; Hsu KW; Hsieh WS; Chi WM; Lee AW; Yang JM; Lin CL; Lee CH
    Dis Markers; 2018; 2018():3835783. PubMed ID: 29849821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compensatory functions of histone deacetylase 1 (HDAC1) and HDAC2 regulate transcription and apoptosis during mouse oocyte development.
    Ma P; Pan H; Montgomery RL; Olson EN; Schultz RM
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):E481-9. PubMed ID: 22223663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC1 and HDAC2 in mouse oocytes and preimplantation embryos: Specificity versus compensation.
    Ma P; Schultz RM
    Cell Death Differ; 2016 Jul; 23(7):1119-27. PubMed ID: 27082454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
    Weinlander E; Somnay Y; Harrison AD; Wang C; Cheng YQ; Jaskula-Sztul R; Yu XM; Chen H
    J Surg Res; 2014 Jul; 190(1):191-7. PubMed ID: 24679699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
    Lin SF; Lin JD; Chou TC; Huang YY; Wong RJ
    PLoS One; 2013; 8(10):e77684. PubMed ID: 24155971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CRISPR-Cas9 repressor for epigenetic silencing of KRAS.
    Liu J; Sun M; Cho KB; Gao X; Guo B
    Pharmacol Res; 2021 Feb; 164():105304. PubMed ID: 33202255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.